Univariable and multivariable analyses of baseline characteristics as predictors of OS
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Univariable analyses | |||
| Sex (male vs female) | 0.66 | 0.40-1.1 | .10 |
| Age at COVID-19 diagnosis (≥75 vs <75 y) | 2.0 | 1.2-3.3 | .004 |
| CIRS (>6 vs ≤6) | 2.8 | 1.4-5.4 | .001 |
| Lymphopenia (ALC ≥1.0 × 109/L vs ALC <1.0 × 109/L) | 1.0 | 0.58-1.9 | .88 |
| Comorbidities | |||
| Hypertension | 1.4 | 0.88-2.4 | .137 |
| Diabetes | 2.0 | 1.2-3.3 | .011 |
| Arrhythmia | 1.5 | 0.87-2.7 | .13 |
| Coronary artery disease | 1.3 | 0.64-2.7 | .44 |
| COPD | 1.4 | 0.67-2.7 | .40 |
| Asthma | 2.4 | 1.05-5.2 | .036 |
| Chronic renal disease | 2.3 | 1.3-4.1 | .004 |
| Hypogammaglobulinemia | 0.67 | 0.39-1.1 | .14 |
| Smoking history (current vs never/former smoker) | 2.3 | 1.1-5.0 | .027 |
| Ever treated vs watch and wait | 0.88 | 0.53-1.4 | .60 |
| Currently treated vs observation | 0.70 | 0.42-1.1 | .15 |
| Current BTKi therapy | 0.80 | 0.47-1.4 | .42 |
| Prior lines of therapy (continuous variable) | 0.98 | 0.78-1.2 | .87 |
| Country of diagnosis | |||
| Spain vs United States | 1.2 | 0.71-2.1 | .47 |
| United Kingdom vs United States | 1.1 | 0.52-2.2 | .86 |
| Multivariable analyses | |||
| Age at COVID-19 diagnosis (≥75 y vs <75 y) | 1.8 | 1.1-3.0 | .028 |
| CIRS (>6 vs ≤6) | 1.6 | 1.0-2.9 | .043 |
| Diabetes | 1.5 | 0.8-2.5 | .172 |
| Asthma | 2.5 | 1.1-5.8 | .025 |
| Chronic renal disease | 1.8 | 1.0-3.4 | .035 |
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Univariable analyses | |||
| Sex (male vs female) | 0.66 | 0.40-1.1 | .10 |
| Age at COVID-19 diagnosis (≥75 vs <75 y) | 2.0 | 1.2-3.3 | .004 |
| CIRS (>6 vs ≤6) | 2.8 | 1.4-5.4 | .001 |
| Lymphopenia (ALC ≥1.0 × 109/L vs ALC <1.0 × 109/L) | 1.0 | 0.58-1.9 | .88 |
| Comorbidities | |||
| Hypertension | 1.4 | 0.88-2.4 | .137 |
| Diabetes | 2.0 | 1.2-3.3 | .011 |
| Arrhythmia | 1.5 | 0.87-2.7 | .13 |
| Coronary artery disease | 1.3 | 0.64-2.7 | .44 |
| COPD | 1.4 | 0.67-2.7 | .40 |
| Asthma | 2.4 | 1.05-5.2 | .036 |
| Chronic renal disease | 2.3 | 1.3-4.1 | .004 |
| Hypogammaglobulinemia | 0.67 | 0.39-1.1 | .14 |
| Smoking history (current vs never/former smoker) | 2.3 | 1.1-5.0 | .027 |
| Ever treated vs watch and wait | 0.88 | 0.53-1.4 | .60 |
| Currently treated vs observation | 0.70 | 0.42-1.1 | .15 |
| Current BTKi therapy | 0.80 | 0.47-1.4 | .42 |
| Prior lines of therapy (continuous variable) | 0.98 | 0.78-1.2 | .87 |
| Country of diagnosis | |||
| Spain vs United States | 1.2 | 0.71-2.1 | .47 |
| United Kingdom vs United States | 1.1 | 0.52-2.2 | .86 |
| Multivariable analyses | |||
| Age at COVID-19 diagnosis (≥75 y vs <75 y) | 1.8 | 1.1-3.0 | .028 |
| CIRS (>6 vs ≤6) | 1.6 | 1.0-2.9 | .043 |
| Diabetes | 1.5 | 0.8-2.5 | .172 |
| Asthma | 2.5 | 1.1-5.8 | .025 |
| Chronic renal disease | 1.8 | 1.0-3.4 | .035 |